Dear Neoplasm -

I am so sorry to hear what you have been going through. I was only on Lyrica (pregabalin) briefly, but discontinued it for other reasons.

Here is a link to the full U.S. Prescribing Information sheet on the drug, http://www.pfizer.com/files/products/uspi_lyrica.pdf

There is a specific discussion of Ophthalmological Effects at Sec. 5.10 that is essentially focused on your concern, but without any discussion of long term effects:

5.10 Ophthalmological Effects

In controlled studies, a higher proportion of patients treated with LYRICA reported blurred vision (7%) than did patients treated with placebo (2%), which resolved in a majority of cases with continued dosing. Less than 1% of patients discontinued LYRICA treatment due to vision related events (primarily blurred vision).

Prospectively planned ophthalmologic testing, including visual acuity testing, formal visual field testing and dilated funduscopic examination, was performed in over 3600 patients. In these patients, visual acuity was reduced in 7% of patients treated with LYRICA, and 5% of placebotreated patients. Visual field changes were detected in 13% of LYRICA-treated, and 12% of placebo-treated patients. Funduscopic changes were observed in 2% of LYRICA-treated and 2% of placebo-treated patients.

Although the clinical significance of the ophthalmologic findings is unknown, inform patients to notify their physician if changes in vision occur. If visual disturbance persists, consider further assessment. Consider more frequent assessment for patients who are already routinely monitored for ocular conditions [see Patient Counseling Information (17.8)].

And this is all that Sec. 17.8 has to say:

17.8 Ophthalmological Effects

Counsel patients that LYRICA may cause visual disturbances. Inform patients that if changes in vision occur, they should notify their physician [see Warnings and Precautions (5.10)].

The most interesting information probably appears in Sec. 6.1 (Adverse Reactions - Clinical Trials Experience) which shows a pattern of dose-dependent reaction among patients with four separate conditions, in each case showing the highest rate of blurry vision (or amblyopia) at the highest recommended dose of 600 mg./day:

Neuropathic Pain Associated with Diabetic Peripheral Neuropathy: 6%
Neuropathic Pain Associated with Postherpetic Neuralgia: 9%
"adjunctive therapy for adult patients with partial onset seizures": 12%
Fibromyalgia: 12%

The good news may be that a quick PubMed search doesn't pick any abstracts pertaining to long-term ophthalmologic effects. However, if your symptoms persist, you might want to consider getting a referral to a Neuro-Ophthalmologist, many of whom work out of medical schools.

Mike